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A b s t r a c t
Introduction: We aimed to examine serum endocan level and the summa-
ry involvement of dyslipidemia, oxidative stress (OS) and inflammation by 
calculation of its comprehensive score (i.e. Dyslipidemia-Oxy-Inflammation 
(DOI) score) in relation to glucoregulation in subjects with prediabetes and 
overt type 2 diabetes (T2D).
Material and methods: A  total of 59 patients with prediabetes and 102 
patients with T2D were compared with 117 diabetes-free controls. Glycated 
hemoglobin (HbA1c), inflammation, OS and lipid parameters were measured. 
Associations of clinical data with HbA1c level were tested with univariate and 
multivariate logistic ordinal regression analysis. HbA1c as a dependent vari-
able is given at the ordinal level (i.e. < 5.7%; 5.7–6.4%, > 6.4%, respectively).
Results: Endocan was significantly higher in the T2D group than in the con-
trols. As endocan concentration rose by 1 unit, the probability for higher 
HbA1c concentration increased by more than 3 times (OR = 3.69, 95% CI: 
1.84–7.01, p < 0.001). Also, a  rise in the dyslipidemia score, oxy score, in-
flammation score and DOI score by 1 unit increased the probability of higher 
HbA1c concentration by 19%, 13%, 51% and 11%, respectively. In the mod-
els, after adjustment for confounding variables, endocan and DOI score re-
mained independent predictors of HbA1c level.
Conclusions: Endocan and DOI score are independently correlated with 
HbA1c in patients with prediabetes and overt T2D.
Key words: inflammation, diabetes, oxidative stress, glycemic control, 
endocan.
Introduction
The prevalence of type 2 diabetes mellitus (T2D) is increasing world-
wide, as are the morbidity and mortality due to its complications [1]. This 
is mostly related to the modern lifestyle that includes changes in the 
eating habits, overnutrition, as well as physical inactivity [2].
Hyperglycemia leads to excessive generation of reactive oxygen spe-
cies (ROS), and when the antioxidant defense capacity is exceeded, it 
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causes a  redox imbalance which could lead to 
formation of a  toxic and damaging milieu. ROS 
trigger several molecular mechanisms, such as 
activating pro-inflammatory signaling pathways, 
increasing secretion of proinflammatory cytokines 
and further leading to chronic systemic inflamma-
tion, activating apoptosis and tissue damage [1]. 
Therefore, it may be regarded that hypergly-
cemia-induced oxidative stress (OS) and chronic 
inflammation play an important role in the devel-
opment of insulin resistance (IR) and overt T2D 
[2, 3]. Not only does IR per se double the risk of 
cardiovascular disease (CVD), it is also related to 
higher rates of coronary artery disease, peripheral 
arterial disease and cerebrovascular disease [2].
Dyslipidemia secondary to IR is a typical find-
ing in T2D [4, 5]. It is caused by increased flux of 
free fatty acids and proinflammatory cytokines 
and adipokines secreted from visceral adipose tis-
sue depots [2]. Apart from stimulating functional 
and structural changes in lipoproteins and protein 
molecules, these cytokines induce abnormalities 
of endothelial cells, and consequently atheroscle-
rosis [6].
It is estimated that CVD are the main cause 
of death in about 80% of subjects with T2D [2]. 
Considering the fact that T2D is an independent 
risk factor for CVD, and since T2D and CVD share 
common underlying pathophysiological mecha-
nisms, it is of great importance to explore some 
novel biomarkers that can help elucidate the 
complex pathological alterations of these disor-
ders [3].
In line with this, endocan is emerging as a nov-
el biomarker of endothelial dysfunction [7, 8] that 
is found to be increased in CVD and T2D. Its ability 
to stimulate endothelial cells to secrete a variety 
of proinflammatory cytokines, promote migration 
of leukocytes, and increase blood vessel perme-
ability makes this proteoglycan a  promising bio-
marker for recognizing increased atherosclerotic 
disease risk burden [9].
Although several previous studies have shown 
higher endocan levels in T2D [8, 10, 11], some oth-
ers showed the opposite, i.e. lower endocan levels 
in T2D than in controls [12]. Therefore, the patho-
physiological role of this biomarker is not com-
pletely elucidated in different stages of diabetes, 
such as prediabetes and overt T2D.
Moreover, since dyslipidemia, OS and chronic 
inflammation are underlying features of T2D [5, 
13, 14], we aimed to examine serum endocan lev-
el and the summary involvement of dyslipidemia, 
oxidative stress (OS) and inflammation by calcu-
lation of its comprehensive score (i.e. Dyslipid-
emia-Oxy-Inflammation (DOI) score) in relation to 




The current case-control study encompassed 
a  total of 59 patients with prediabetes and 102 
with T2D, who were compared with 117 controls. 
The participants were consecutively recruited 
when visiting the Primary Health Care Center in 
Podgorica, Montenegro, for metabolic evaluation 
by performing laboratory analyses in a  period 
from May 2017 to July 2017.
Each participant filled in a questionnaire con-
sisting of questions regarding demographic char-
acteristics, lifestyle habits (e.g., data about dura-
tion of T2D (years), alcohol consumption, cigarette 
smoking) and somatic illnesses.
The inclusion criteria for participants with 
prediabetes and T2D were taken from the  2017 
American Diabetes Association Standards of Di-
abetes Care [15]. Participants were considered 
to have T2D if previously diagnosed T2D or with 
glycated hemoglobin (HbA1c) level ≥ 6.5% on two 
different determinations, or with at least two fast-
ing glucose levels ≥ 7.0 mmol/l, or with a random 
glucose level of ≥ 11.1 mmol/l, or with a glucose 
level ≥ 11.1 mmol/l, 2 h after an oral glucose tol-
erance test (OGTT) with 75 g anhydrous glucose 
dissolved in water. 
Participants were considered to have predia-
betes if they were not using any antihyperglyce-
mic medications and if they had a fasting glucose 
ranging between ≥ 5.6 mmol/l and < 7.0 mmol/l, 
but 2 h after OGTT had a  plasma glucose level 
between 7.8 mmol/l and 11.1 mmol/l, or if they 
exhibited a HbA1c level between 5.7% and 6.4%. 
The control group consisted of diabetes-free 
participants who were not using any antihypergly-
cemic medications, with a HbA1c level lower than 
5.7% and fasting glucose lower than 5.6 mmol/l.
Participants with severe anemia, a  history of 
acute myocardial infarction or stroke in the last 
6 months, type 1 diabetes mellitus, high-sensitiv-
ity C-reactive protein (hsCRP) > 10 mg/l, thyroid 
dysfunction, hepatic disease other than steatosis, 
renal disease other than diabetic nephropathy and 
with estimated glomerular filtration rate (eGFR) 
< 15 ml/min/1.73 m2, patients with ethanol con-
sumption > 20 g/day and pregnancy were exclud-
ed from the study.
Each participant signed consent and was well 
informed about the aim of the study. The Ethics 
Committee of the Primary Health Care Center in 
Podgorica, Montenegro approved the protocol of 
the study. 
A  total of 86% of T2D participants used oral 
antihyperglycemics (of them metformin, sulfo-
nylureas, and inhibitors of dipeptidyl peptidase 4 
(DPP-4 inhibitors) were used by 94%, 8%, and 10% 
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of patients, respectively), whereas 30% of them 
were on insulin therapy. There were no participants 
in the control and prediabetes group who used an-
tihyperglycemic medications, as would be expected 
based on inclusion/exclusion criteria. Hypolipidem-
ics were used by 24%, 29% and 47% of participants 
in the control, prediabetes and T2D group, respec-
tively. All of them used statins in the control and 
prediabetes group, whereas 96% of participants in 
the T2D group used statins and 4% of them used 
fibrates. Antihypertensive drugs were used by 46%, 
63% and 83% of participants in the control, predia-
betes and T2D group, respectively.
Anthropometric measurements were taken 
from each participant (i.e., body height (cm), body 
weight (kg), and waist circumference (WC), where-
as body mass index (BMI) was calculated).
Systolic (SBP) and diastolic blood pressure 
(DBP) were measured with a  mercury sphygmo-
manometer after the participant’s rest for 5 min-
utes. All measurements were taken by the same 
nurse and recorded the average of the 3 measure-
ments taken on the right arm.
The estimation of glomerular filtration rate 
(eGFR
MDRD) was calculated by using Modification 
of Diet in Renal Disease Study equation, as de-
scribed previously [4].
Methods
The phlebotomy was performed and blood 
samples were taken in the morning after an 
overnight fast of at least 8 h. Samples collected 
in tubes with serum separator and clot activator 
were left to clot for 30 min, and thereafter were 
centrifuged at room temperature for 10 min at 
3000xg. Afterwards, serum samples were divided 
into aliquots and stored at –80°C for determina-
tion of endocan, high-sensitivity C-reactive pro-
tein (hsCRP) and OS markers, whereas the remain-
ing sera were analyzed immediately for fasting 
glucose, lipid parameters (i.e., triglycerides (TG), 
total cholesterol, high-density lipoprotein choles-
terol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C)) and creatinine. Samples of whole blood 
in tubes containing K
2EDTA were used for deter-
mination of HbA
1c levels using the immunoturbidi-
metric method. All these analyses were performed 
on Roche Cobas c501 chemistry analyzer (Roche 
Diagnostics GmbH, Mannheim, Germany). Serum 
hsCRP levels were measured by nephelometric 
assay (Behring Nephelometer Analyzer, Marburg, 
Germany). Endocan levels were measured using 
an enzyme-linked immunosorbent commercial as-
say (ab213776 – Human ESM1 ELISA Kit, Abcam, 
Cambridge, UK). Ninety-six well plates were coat-
ed with mouse monoclonal antibody specific for 
ESM1/endocan with samples added afterwards. 
A biotinylated detection polyclonal antibody from 
goat specific for ESM1/endocan was added sub-
sequently and then rinsed three times in PBS 
or TBS buffer. Avidin-biotin-peroxidase complex 
was added (PBS or TBS buffer washed away un-
bound conjugates). HRP substrate TMB was add-
ed to visualize HRP enzymatic reaction. TMB was 
catalyzed by HRP resulting with the blue colored 
product. After adding TMB stop solution the blue 
product becomes yellow which is proportional to 
the concentration of human ESM1/endocan. The 
absorbance was read at 450 nm in a microplate 
reader for 30 min.
Determination of prooxidant-antioxidant bal-
ance (PAB) was performed using 3,3′, 5,5′-te-
tramethylbenzidine as a  chromogen [16]. Ad-
vanced oxidation protein products (AOPP) were 
measured by a method that used a reaction with 
glacial acetic acid and potassium iodide [17]. To-
tal oxidative status (TOS) was determined spec-
trophotometrically using o-dianisidine optimized 
by Erel [18]. Total antioxidative status (TAS) was 
evaluated spectrophotometrically using ABTS as 
a  chromogen [19]. Total protein sulfhydryl (SH-) 
groups were measured spectrophotometrically 
using 5,5′-dithiobis (2- nitro benzoic acid) [20]. 
Calculation of novel scores
Since we aimed to explore the summary effect 
of the key risk factors in patients with prediabetes 
and T2D (i.e. dyslipidemia, OS and inflammation), 
we calculated the DOI score as the sum of the dys-
lipidemia score, oxy score and inflammation score 
[21, 22]. 
The dyslipidemia score was calculated after 
standardization of all the variables and calculat-
ing z scores for HDL-C, LDL-C, and TG and using 
mean and standard deviation calculated from the 
healthy control group. Afterwards, standardized 
HDL-C was subtracted from the average of the 
standardized variables (TG + LDL-C) [21, 22].
The oxy score was obtained by subtraction of 
the protective score (i.e. which was calculated as 
an average of standardized antioxidant variables 
(total SH- groups and TAS)) from the damage 
score (i.e. which was calculated as the average of 
standardized prooxidant factors (AOPP, TOS, and 
PAB)) [23]. 
The inflammation score was determined after 
standardization of hsCRP [21].
Statistical analysis
Before the start of the study, it was calculat-
ed that to achieve a power of 80% and a level of 
significance of 5% (two-sided) for detecting a true 
difference in means between the test and the ref-
erence group, a total of 111 participants in each 
of the control and T2D group was required. We 
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included 10% more participants, but due to ex-
clusion criteria, finally a total of 117 participants 
were included in the control group and 102 par-
ticipants in the T2D group. However, we could not 
perform a sample size determination for the group 
with prediabetes because there were no previous 
studies that examined endocan levels in patients 
with prediabetes.
After testing data distribution by Shapiro-Wilk 
test, log-normally distributed data were presented 
as the geometric mean (95% confidence interval – 
95% CI) and skewed distributed data as the medi-
an (interquartile range). Comparison of log-normal 
data was performed by one-way ANOVA with the 
Tukey post hoc test and comparison of skewed data 
was performed by the Kruskal-Wallis test when 
testing differences between three groups, and the 
Mann-Whitney test when testing the difference be-
tween two groups. Categorical data were presented 
as absolute and relative frequencies and compared 
by the c2 test for contingency tables. Spearman’s 
bivariate correlation analysis was used for testing 
the associations between clinical parameters, and 
the data were presented as correlation coefficients 
(ρ). In-depth independent associations of clinical 
data with HbA
1c level were tested with univariate 
and multivariate logistic ordinal regression analysis. 
Independent variables were given as continuous or 
dichotomous with no multicollinearity among them 
and each had an identical effect at each cumulative 
split of the ordinal dependent variable. Also, con-
tinuous independent variables included in models 
were correlated with HbA
1c. HbA1c as a dependent 
variable is given at the ordinal level (1 for a HbA
1c 
Table I. Demographic characteristics of tested population groups
Parameter Control group Prediabetes T2D P-value#
N (male) 117 (30%) 59 (34%) 102 (53%) 0.001
Age [years] 58 (56–60) 62 (60–65)a** 65 (63-67)a** < 0.001
BMI [kg/m2] 27.3 (26.6–28.1) 28.5 (27.4–29.6) 30.3 (29.5–31.2)a**,b* < 0.001
WC [cm]† 95 (87–102) 96 (91–102) 104 (97–110)a**,b** < 0.001
SBP [mm Hg]† 136 (124–146) 136 (126–150) 133 (126–148) 0.642
DBP [mm Hg]† 84 (77–91) 85 (76–92) 84 (77–94) 0.921
Smokers, n (%) 25 (21) 19 (32) 14 (14) 0.021
Antihyperglycemics, n (%): – – 88 (86) –
Metformin 83 (94)
Sulfonylurea 7 (8)
DPP-4 inhibitors 9 (10)
Insulin, n (%) – – 31 (30) –
Hypolipidemics, n (%): 28 (24) 17 (29) 48 (47) 0.001
Statins 28 (100) 17 (100) 46 (96)
Fibrates – – 2 (4)
Antihypertensives, n (%): 54 (46) 37 (63) 85 (83) < 0.001
ACE 47 (87) 30 (81) 67 (79)
CCB 3 (5) 1 (3) 8 (9)
ARB 3 (5) 1 (3) 8 (9)
Beta-blockers 15 (32) 7 (19) 27 (32)
Thiazide diuretics 26 (48) 18 (49) 49 (58)
Duration of diabetes, years – – 5 (1–10) –
Data are presented as geometric mean (95% CI) and compared by one-way ANOVA with Tukey post hoc test. †Data are presented as 
median (interquartile range) and compared by Kruskal-Wallis or Mann-Whitney test dependent on the number of examined groups. #P for 
one way ANOVA or Kruskal-Wallis test. aSignificantly different from the control group, bsignificantly different from the prediabetes group. 
*P < 0.05; **p < 0.01. BMI – body mass index, WC – waist circumference, SBP – systolic blood pressure, DBP – diastolic blood pressure, 
DPP-4 inhibitors – inhibitors of dipeptidyl peptidase 4, ACE inhibitors – angiotensin converting enzyme inhibitors, CCB – calcium channel 
blocker, ARB – angiotensin receptor blocker.
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concentration less than 5.7%; 2 for a  HbA1c level 
between 5.7 and 6.4%; and 3 for a HbA1c concen-
tration higher than 6.4% or lower only if the pa-
tient self-reported T2D). Data from logistic ordinal 
regression analyses were presented as odds ratio 
(OR) and 95% CI. The explained variation in HbA
1c 
level in the tested population was given by the 
Nagelkerke R2 value.
All statistical testing was performed using the 
statistical program IBM SPSS Statistics version 22 
(SPSS Inc., Chicago, Ilinois, USA). The statistical 
significance level was set at two-sided p < 0.05.
Results
There were unequal numbers of women and 
men were in the tested groups. There were un-
equal numbers of women and men in the tested 
groups. The youngest examinees were those in the 
control group. Patients with T2D had the highest 
BMI and WC compared to controls and prediabe-
tes patients. Smokers were most prevalent in the 
prediabetes group. Patients on hypolipidemic and 
antihypertensive therapies were more frequent 
among patients with T2D (Table I).
Most of the tested clinical markers, except for 
TAS, TOS and total SH groups, were significantly 
different between tested groups (Table II). There 
were significant differences in glucose and HbA
1c 
level between all three groups, being the highest 
in the T2D and the lowest in the control group. The 
lowest TC, LDL-C and PAB levels were in the group 
with T2D. HDL-C level was the highest in the con-
trol group. Creatinine concentration was the high-
est in the T2D group. Patients with prediabetes 
and T2D had significantly higher hsCRP and AOPP 
levels than the control group. TG and endocan lev-
els were significantly different only between the 
control group and T2D, being higher in the group 
of patients with T2D. 
The Kruskal-Wallis test showed significant dif-
ferences in all calculated scores and all of them 
were significantly lower in the control group com-
pared to the prediabetes and T2D groups (Table III). 
The scores showed no difference between the pre-
diabetes and T2D groups.
Results from Spearman’s correlation analysis 
between HbA1c and other variables are present-
ed in Table IV. Significant positive correlations 
were established between HbA1c and the follow-
ing variables: years of age, BMI, WC, glucose, TG, 
creatinine, hsCRP, AOPP, TAS, total SH groups and 
calculated scores in all participants. Significant 
negative correlations were observed between 
Table II. Clinical markers of tested population groups
Parameter Control group Prediabetes T2D P-value#
Glucose [mmol/l] 5.4 (5.2–5.6) 6.1 (5.8–6.5)a* 7.9 (6.7–9.6)a*,b* < 0.001
HbA1c (%) 5.3 (5.1–5.5) 5.9 (5.7–6.0)
a* 7.1 (6.5–8.9)a*,b* < 0.001
Total cholesterol [mmol/l]† 5.80 (5.57–6.04) 6.02 (5.64–6.43) 5.23 (5.02–5.46)a**,b** < 0.001
HDL cholesterol [mmol/l]† 1.51 (1.44–1.58) 1.31 (1.20–1.44)a** 1.20 (1.14–1.26)a** <0.001
LDL cholesterol [mmol/l]† 3.42 (3.23–3.63) 3.73 (3.42–4.07) 2.92 (2.72–3.13)a**,b** < 0.001
TG [mmol/l]† 1.54 (1.42–1.67) 1.77 (1.56–2.00) 2.06 (1.88–2.26)a** < 0.001
Creatinine [μmol/l]† 70 (62–84) 72 (66–71) 80 (67–93)a*,b* < 0.001
eGFRMDRD [mL/min/1.73 m
2]† 82 (73–91) 77 (70–86) 73 (62–86) a* 0.001
HsCRP [mg/l] 0.88 (0.75–1.04) 1.31 (1.02–1.68)a* 1.54 (1.29–1.84)a** < 0.001
AOPP [μmol/l] 38.84 (36.89–40.89) 45.82 (41.57–50.49)a** 47.12 (44.14–50.31)a** < 0.001
PAB [HKU] 103 (96–110) 104 (93–115) 88 (81–95)a*,b* 0.005
TOS [μmol/l]† 9.09 (7.81–10.58) 10.30 (8.22–12.90) 11.09 (9.63–12.76) 0.180
TAS [μmol/l]† 1130 (1077–1186) 1120 (1075–1166) 1162 (1108–1220) 0.562
Total SH- groups [μmol/l] 0.237 (0.219–0.256) 0.270 (0.248–0.295) 0.269 (0.248–0.293) 0.065
Endocan [ng/ml] 0.282 (0.246–0.323) 0.308 (0.248–0.383) 0.395 (0.330–0.473)a** 0.002
Data are presented as geometric mean (95% CI) and compared by one-way ANOVA with Tukey post hoc test. †Data are presented as median 
(interquartile range) and compared by Kruskal-Wallis test or Mann-Whitney test dependent on the number of examined groups. #P for 
one-way ANOVA or Kruskal-Wallis test. aSignificantly different from the control group, bsignificantly different from the prediabetes group. 
*P < 0.05; **p < 0.01. HbA
1c
 – glycated hemoglobin, HDL cholesterol – high-density lipoprotein cholesterol, LDL cholesterol – low-density 
lipoprotein cholesterol, TG – triglycerides, eGFR
MDRD
 – estimated glomerular filtration rate, HsCRP – high-sensitivity C-reactive protein, 
AOPP – advanced oxidation protein products, PAB – prooxidant-antioxidant balance, TOS – total oxidative status, TAS – total antioxidative 
status, Total SH- groups – total protein sulfhydryl (SH-) groups.
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HbA1c and total cholesterol, HDL-C, LDL-C and PAB 
in all participants. 
Further we wanted to test whether endocan 
and scores were independently associated with 
HbA1c concentration using logistic ordinal regres-
sion analysis (Table V). Significant ORs obtained in 
univariate analysis were evident for all tested pa-
rameters. This analysis indicated that a rise in en-
docan concentration by 1 unit increased the prob-
ability of higher HbA1c concentration 3 times (OR = 
3.69, 95% CI: 1.84–7.01, p < 0.001). Also, a rise in 
dyslipidemia score, oxy score, inflammation score 
and DOI score by 1 unit increased the probability 
of higher HbA1c concentration by 19%, 13%, 51% 
and 11%, respectively. When tested in different 
models, endocan, dyslipidemia score and DOI score 
were found to be independent predictors of HbA1c 
level. In all four models (Models 1–4), as endocan 
concentration rose by 1 unit, the probability of 
a higher HbA1c level increased by 2.66, 2.31, 2.64 
and 2.28 times, respectively. As dyslipidemia score 
(Model 1) and DOI score (Model 4) rose by 1 unit, 
the probability of a higher HbA1c level increased by 
31% and 9%, respectively. Nagelkerke R2 for Models 
1–4 were 0.366, 0.395, 0.395 and 0.359, respec-
tively, which means that 36.6%, 39.5%, 39.5% and 
35.9% of variation in HbA1c level could be explained 
by parameters included in the models.
Discussion
To the best of our knowledge, this is the first 
study that has estimated serum endocan levels 
and the summary involvement of dyslipidemia, 
OS and inflammation by comprehensive score 
calculation (i.e., DOI score) in relation to gluco-
regulation in patients with prediabetes and T2D. 
Although previous studies investigated separately 
some of the biomarkers that were used for calcu-
lation of these scores in patients with T2D, we pre-
sumed that the mutual effect of several of these 
biomarkers calculated as DOI score could better 
explain the complex interrelationship between 
glucoregulation and these features, rather than 
examining each single biomarker. Additionally, en-
docan is not explored thoroughly in different stag-
es of diabetes, such as prediabetes and overt T2D. 
In line with this, we have shown that serum 
endocan levels were significantly higher in T2D 
group than in the controls. Although median val-
ues of endocan levels were higher in the predia-
Table III. Dyslipidemia score, oxy score, inflammation score and DOI Score in examined groups
Parameter Controls Prediabetes T2D P-value
Dyslipidemia score –0.72 (–1.89)–(0.14) –0.19 (–1.10)–(1.41)a* 0.23 (–1.04)–(1.14)a** 0.003
Inflammation score –0.59 (–0.78)–(–0.26) –0.28 (–0.71)–0.40a* –0.31 (–0.67)–0.27a** 0.002
Oxy score 4.38 (2.74–6.70) 6.57 (4.16–9.11)a* 6.65 (4.63–10.26)a* < 0.001
DOI score 3.55 (0.68–6.14) 7.41 (2.62–10.50)a* 6.99 (2.70–11.92)a* < 0.001
Data are given as median (interquartile range) and compared by Kruskal-Wallis test or Mann-Whitney test dependent on the number of 
examined groups. aSignificantly different from the control group. *P < 0.05; **p < 0.01.
Table IV. Spearman’s correlation analysis between 





SBP [mm Hg] 0.002
Glucose [mmol/l] 0.744**
Total cholesterol [mmol/l] –0.165*
HDL cholesterol [mmol/l] –0.334**














*P < 0.05, **p < 0.01, HbA
1c
 – glycated hemoglobin, BMI – body 
mass index, WC – waist circumference, SBP – systolic blood 
pressure, DBP – diastolic blood pressure, HDL cholesterol – high-
density lipoprotein cholesterol, LDL cholesterol – low-density 
lipoprotein cholesterol, TG – triglycerides, HsCRP – high-sensitivity 
C-reactive protein, AOPP – advanced oxidation protein products, 
PAB – prooxidant-antioxidant balance, TOS – total oxidative status, 
TAS – total antioxidative status, Total SH- groups – total protein 
sulfhydryl (SH-) groups.
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Table V. Estimated odds ratios after ordinal regression analysis for HbA
1c cut-offs as dependent variable
Parameter Unadjusted Nagelkerke R2
OR (95% CI) P-value
Endocan [ng/ml] 3.69 (1.84–7.01) < 0.001 0.076
Dyslipidemia score 1.19 (1.06–1.34) 0.004 0.034
Oxy-score 1.13 (1.07–1.20) < 0.001 0.083
Inflammation score 1.51 (1.16–1.96) 0.002 0.042
DOI score 1.11 (1.06–1.16) < 0.001 0.102
Model 1 Adjusted Nagelkerke R2
OR (95% CI) P-value
Endocan [ng/ml] 2.66 (1.32–5.37) 0.006 0.366
Dyslipidemia score 1.31 (1.12–1.53) 0.001
Model 2 Adjusted Nagelkerke R2
OR (95% CI) P-value
Endocan [ng/ml] 2.31 (1.03–5.16) 0.042 0.395
Oxy score 0.98 (0.89–1.07) 0.628
Model 3 OR (95% CI) P-value Nagelkerke R2
Endocan [ng/ml] 2.64 (1.29–5.39) 0.008 0.395
Inflammation score 1.17 (0.21–2.17) 0.230
Model 4 OR (95% CI) P-value Nagelkerke R2
Endocan [ng/ml] 2.28 (1.02–5.10) 0.043 0.359
DOI score 1.09 (1.03–1.15) 0.001
Data are given as OR (95% CI). Model 1 included continuous variables: age, WC, creatinine, hsCRP, endocan, dyslipidemia score and 
categorical variables: gender, smoking habits, antihypertensive therapy, hypolipidemic therapy. Model 2 included continuous variables: 
age, WC, creatinine HDL-c, TG, hsCRP, endocan, oxy score and categorical variables: gender, smoking habits, antihypertensive therapy, 
hypolipidemic therapy. Model 3 included continuous variables: age, WC, creatinine HDL-c, TG, endocan, inflammation score and categorical 
variables: gender, smoking habits, antihypertensive therapy, hypolipidemic therapy. Model 4 included continuous variables: age, WC, 
creatinine, endocan, DOI score and categorical variables: gender, smoking habits, antihypertensive therapy, hypolipidemic therapy
betes than the control group, the differences be-
tween these two groups did not reach statistical 
significance, perhaps due to the small sample size 
group of patients with prediabetes. On the other 
hand, the lack of significant difference in endocan 
levels between the prediabetes and T2D group, 
even though median values of endocan levels 
were higher in T2D, might be explained by the fact 
that patients with T2D used anti-hyperglycemic 
medications, unlike patients with prediabetes in 
our study, which might affect the results [11].
The current study has also for the first time 
shown that all examined novel scores (i.e., oxy-
score, inflammation, dyslipidemia and its sum-
mary DOI score) were significantly higher in the 
prediabetes and T2D group, as compared with the 
control group. Furthermore, our research showed 
that endocan and summary DOI score are inde-
pendently correlated with HbA1c level in examined 
population groups. 
Inflammation is one of the underlying risks of 
β cell damage and IR in patients with T2D [2]. Fur-
thermore, the vicious circle of hyperinsulinemia 
and hyperglycemia and the prolonged burden of 
pro-inflammatory cytokines lead to deeper im-
balance in the lipoprotein levels, promote lipid 
peroxidation, as well as oxidative modification of 
protein structures, and aggravate endothelial dys-
function and atherosclerosis [6, 24]. Having these 
facts in mind, a  novel inflammation biomarker 
of endothelial dysfunction, such as endocan [3], 
and a  comprehensive DOI score which includes 
all these key features of T2D may be important 
determinants of the progression of this metabolic 
disorder.
In the study of Balamir et al. [25], serum en-
docan levels were shown to be associated with 
endothelial dysfunction in T2D patients. Also, 
a recent study of Lv et al. [26] suggested that se-
rum endocan might be a  reliable parameter for 
Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated 
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the early diagnosis of subclinical atherosclerosis 
in T2D patients, showing its independent relation-
ship with carotid intima-media thickness. Further-
more, higher levels of endocan were also reported 
in T2D patients with acute ST-segment elevation 
myocardial infarction compared with the newly di-
agnosed untreated T2D patients and healthy con-
trols [8]. Moreover, Arman et al. [11] showed a sig-
nificant decrease in endocan levels in patients 
with T2D after 3-month follow-up with lifestyle 
modification and anti-hyperglycemic treatment.
The potential of endocan to stimulate secretion 
of proinflammatory cytokines by endothelial cells, 
as well as its ability to enhance the permeability 
of blood vessels may increase atherosclerotic dis-
ease risk burden [9], especially in subjects with 
prediabetes and T2D. Since poor glucoregulation 
represents an important risk factor for CVD mor-
bidity and mortality [15, 24], further prospective 
studies are needed to elucidate whether determi-
nation of examined biomarkers (i.e. endocan and 
DOI scores) in a timely manner may be useful to 
detect increased atherosclerotic risk and also to 
elucidate whether the lowering of these biomark-
ers can enable prevention of T2D and/or its vascu-
lar complications. 
Limitations of the current study need to be 
mentioned. The majority of examined participants, 
especially those with T2D, were on some kind of 
medication treatment, which might influence the 
results [3, 11, 27]. Namely, previous studies have 
shown that antihypertensive medications, such as 
amlodipine and valsartan, may lower serum endo-
can levels and hsCRP [28]. Moreover, metformin 
was shown to decrease levels of endocan and some 
endothelial markers [11, 29], whereas antilipemic 
agents exert beneficial effects on endothelial cells, 
and consequently lower endocan levels, also [30]. 
Above this, the duration of diabetes and its com-
plications may also influence examined biomark-
ers. Additionally, diseases that were excluded from 
the study were self-reported by participants, which 
might be a source of bias, also. Therefore, new re-
search is needed to further explore endocan levels 
and their relation with OS, inflammation and dys-
lipidemia in patients with prediabetes and newly 
diagnosed T2D. Furthermore, environmental and 
genetic factors [31, 32] included in the glucose ho-
meostasis regulatory mechanisms which may play 
an important role in the occurrence of T2D have 
not been explored in the current study, but might 
have influenced the obtained results.
On the other hand, the strength of our study is 
the fact that, beside endocan, we explored a rela-
tively wide spectrum of OS markers and calculated 
a novel summary score of the key features of T2D 
(i.e. the DOI score) in order to gain deeper insight 
into the cardiometabolic changes in prediabetes 
and T2D.
In conclusion, the current study has for the 
first time shown that endocan and a novel score 
for dyslipidemia, oxidative stress and inflamma-
tion (DOI score) are independently correlated 
with HbA
1c in patients with prediabetes and T2D. 
Knowing that poor glucoregulation represents an 
important risk factor for CVD, future studies are 
needed to examine whether determination of 
these biomarkers in a timely manner may be use-
ful to detect atherosclerotic disease risk burden 
in (pre)diabetes, and to investigate whether low-
ering it can enable prevention of T2D and/or its 
cardiometabolic complications. 
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